2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1710 Ogt links nutrient-responsive o-glcnac signaling to HCF1-mediated transcription in acute myeloid leukemia

Sizhe Yang, Yabin Liu2, Huimin Li3, Yun Tan, PhD4
1 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
3 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
4 Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Background: Acute myeloid leukemia (AML) cells undergo extensive metabolic reprogramming to support proliferation and maintain an immature cellular state. Beyond supplying energy and biosynthetic intermediates, nutrient metabolism generates signals that can be interpreted by the transcriptional machinery. The hexosamine biosynthetic pathway integrates glucose, amino acid, acetyl-CoA, and nucleotide metabolism to generate UDP-GlcNAc, the donor substrate used by O-linked β-N-acetylglucosamine transferase (OGT) for protein O-GlcNAcylation. O-GlcNAcylation may therefore function as a nutrient-responsive signal that connects metabolic availability with transcriptional regulation. However, whether this metabolic–transcriptional interface is altered in AML and how OGT contributes to leukemia-associated gene regulation remain incompletely understood.

Results: To determine whether O-GlcNAc signaling is altered in AML, we first analyzed large-scale proteomic datasets comprising AML blasts from 374 patients and CD34-positive hematopoietic stem and progenitor cells (HSPCs) from 6 healthy donors. O-GlcNAc-modified proteins were globally increased in AML, suggesting that leukemia cells exist in an enhanced O-GlcNAc signaling state. We independently validated this observation by flow cytometric analysis of primary samples from 20 patients with AML and CD34-positive HSPCs from 5 healthy donors. Global O-GlcNAc levels were significantly higher in AML blasts than in normal HSPCs, establishing increased protein O-GlcNAcylation as a recurrent metabolic feature of AML.
To assess the functional contribution of OGT, we depleted OGT using independent shRNAs in human AML cell lines. OGT depletion produced a modest but reproducible reduction in AML cell proliferation. Transcriptomic profiling demonstrated that OGT loss altered leukemia-associated transcriptional programs and induced a prominent innate immune response, characterized by coordinated upregulation of interferon-stimulated genes, including ISG15, IFIT1, IFIT3, IFI6. These findings suggest that OGT contributes to the maintenance of a leukemia-associated transcriptional state that restrains endogenous immune and cellular stress responses.
We next performed OGT ChIP-seq to define the chromatin regulatory network associated with OGT. OGT preferentially occupied transcriptionally active regulatory regions, and motif analysis of OGT-bound loci revealed significant enrichment of THAP11–ZNF143 motifs. OGT occupancy was also markedly enriched at previously defined HCF1-binding regions, implicating OGT in the HCF1–THAP11–ZNF143 transcriptional network. Consistently, IP–mass spectrometry identified HCF1 as a prominent OGT-interacting protein. Integration of these chromatin and proteomic data supports a model in which OGT associates with the HCF1–THAP11–ZNF143 complex to connect nutrient-responsive O-GlcNAc signaling with transcriptional regulation. The contribution of this regulatory network to AML has not previously been systematically investigated.
To determine whether OGT could be pharmacologically targeted beyond conventional UDP-GlcNAc-competitive inhibition, we performed a DNA-encoded library screen and identified an OGT-binding small molecule that bound independently of UDP-GlcNAc competition. This compound markedly inhibited AML cell proliferation, despite the relatively modest phenotype produced by partial OGT depletion. These findings suggest that the compound may perturb an allosteric, protein-interaction-dependent, or other noncanonical function of OGT that is not fully captured by incomplete genetic depletion.

Conclusions: AML is characterized by an enhanced O-GlcNAc modification state relative to normal CD34-positive HSPCs. Beyond its canonical role as a glycosyltransferase, OGT associates with an HCF1–THAP11–ZNF143 transcriptional network that links nutrient-responsive signaling to leukemia-associated gene regulation and restraint of intrinsic interferon responses. The identification of a UDP-GlcNAc-independent OGT-binding compound with antileukemic activity further reveals a potentially actionable noncanonical function of OGT. Together, these findings define an unrecognized metabolic–transcriptional regulatory network in AML and provide a rationale for targeting OGT beyond its canonical substrate-binding mechanism.

Sizhe Yang: No relevant conflicts of interest to declare.